Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer - Related Studies

Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer

This study has been completed.

Study NCT00034151. Last updated on November 6, 2008. Information provided by OncoGenex Pharmaceuticals

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Ovarian Cancer

2	Additional conditions recognized in this trial
		Ovarian Neoplasms

3	More general conditions related to this trial
		Adnexal Diseases
		Endocrine Gland Neoplasms
		Endocrine System Diseases
		Genital Diseases, Female
		Genital Neoplasms, Female
		Gonadal Disorders
		Neoplasms
		Neoplasms by Site
		Ovarian Diseases
		Urogenital Neoplasms

4	Additional drug interventions recognized in this trial
		Paclitaxel

5	More general drug interventions related to this trial
		Antimitotic Agents
		Antineoplastic Agents
		Antineoplastic Agents, Phytogenic
		Mitosis Modulators
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Therapeutic Uses
		Tubulin Modulators

6	Sponsors listed in this trial
		OncoGenex Pharmaceuticals